Latigo Biotherapeutics (LTGO) Corporate presentation summary

Strategic vision and market opportunity

• Focused on transforming pain management by developing innovative, non-opioid therapies targeting significant unmet needs in acute and chronic pain.

• Late-stage clinical portfolio centers on differentiated Na 1.8 inhibitors, with lead candidates Onzotrigine for acute pain and LTG-321 for chronic pain.

• Raised approximately $397 million in an upsized IPO, providing a cash runway into 2029.

• Multiple clinical milestones anticipated in the second half of 2027.

Clinical pipeline and trial highlights

• Onzotrigine demonstrated the highest analgesic effect in abdominoplasty trials, with results published in NEJM.

• Phase 3 bunionectomy and safety trials for Onzotrigine are planned for initiation in 2H 2026, with topline results expected in 2H 2027.

• LTG-321, targeting chronic pain, has shown superior analgesic effects in cold pressor tests and is in Phase 2 trials for osteoarthritis.

• Onzotrigine's abdominoplasty trial may serve as one of two pivotal trials required for regulatory approval in moderate to severe acute pain.

Differentiation and clinical outcomes

• Onzotrigine high dose showed 50% greater analgesic effect than Vicodin and 30% greater than suzetrigine, with a 2.3x faster onset of pain relief.

• Achieved a 52% opioid-free rate in trials, meeting FDA endpoints for opioid-sparing claims.

• Demonstrated a favorable safety profile, with adverse event rates lower than placebo and no significant safety concerns.

• Higher Na 1.8 target inhibition at the nerve site supports clinical efficacy over competitors.